 
CLINICAL RESEARCH PROTOCOL   
 
 
A RANDOMIZED, DOUBLE-BLIND,  PLACEBO CONTROLLED, MU LTI-CENTER STUDY TO ASSESS 
THE EFFECTS OF RANOLAZINE IN SUBJECTS WITH PULMONARY HYPERTENSION AND RIGHT 
VENTRICULAR DYSFUNCTION USING CARDIOVASCULAR MRI  
 
 
 
 
Funding Sponsor:  
Gilead Science Inc  
 
Study Product:  
Ranolazine    
 
 
 
 Initial version:  v1 March 9, 2016  
Amended:   
  
Targeting RV in PAH  Page 2 
Version1  
 
 
Table of Contents 
 
1 STUDY FLOWCHART ............................................................................................................... ............ 6 
2 INTRODUCTION .................................................................................................................. .................. 9  
2.1 BACKGROUND  .............................................................................................................................. ..... 9 
2.2 INVESTIGATIONAL AGENT  ................................................................................................................. 10  
2.2.1 Description ................................................................................................................... .......... 10 
2.2.2 Mechanism of  Action ........................................................................................................... ... 10 
2.2.3 Pharmacokinetics .............................................................................................................. ..... 10 
2.2.4 Absorption and Distribution ................................................................................................... . 10 
2.2.5 Metabolism and Excretion ......................................................................................................  11 
2.3 PRECLINICAL DATA .......................................................................................................................... 11  
2.4 CLINICAL DATA TO DATE .................................................................................................................. 11  
2.5 DOSE RATIONALE AND RISK/BENEFITS .............................................................................................. 12  
3 STUDY OBJECTIVES .............................................................................................................. ............ 12  
4 STUDY D ESIGN .................................................................................................................. ................. 12  
4.1 GENERAL DESIGN  ............................................................................................................................ 1 2 
4.2 PRIMARY STUDY ENDPOINTS  ............................................................................................................ 13  
4.3 EXPLORATORY ENDPOINTS  .............................................................................................................. 13  
4.3.1 Outcomes ...................................................................................................................... ......... 13 
4.3.2 CMR ........................................................................................................................... ............ 13  
4.3.3 Metabolism .................................................................................................................... ......... 13 
4.3.4 MicroRNA ...................................................................................................................... ......... 13 
4.3.5 Health outc ome SF-36 .......................................................................................................... . 13 
5 SUBJECT SELECTION AND WITHDRAWAL .................................................................................... 14  
5.1 INCLUSION CRITERIA  ........................................................................................................................ 14  
5.2 EXCLUSION CRITERIA  ....................................................................................................................... 15  
5.3 EARLY WITHDRAWAL OF SUBJECTS  .................................................................................................. 15  
6 STUDY DRUG .................................................................................................................... .................. 16  
6.1 DESCRIPTION  .............................................................................................................................. .... 16 
6.2 TREATMENT REGIMEN  ...................................................................................................................... 16  
6.3 METHOD FOR ASSIGNING SUBJECTS TO TREATMENT GROUPS  ........................................................... 16  
6.4 PREPARATION , PACKAGING AND ADMINISTRATION OF STUDY DRUG ................................................... 17  
6.5 SUBJECT COMPLIANCE MONITORING  ................................................................................................ 17  
6.6 PRIOR AND CONCOMITANT THERAPY  ................................................................................................ 17  
6.7 BLINDING OF STUDY DRUG ............................................................................................................... 18  
6.8 RECEIVING , STORAGE , DISPENSING AND RETURN  ............................................................................. 18  
6.8.1 Receipt of Dr ug Supp lies ...................................................................................................... . 18 
6.8.2 Storage ....................................................................................................................... ............ 18  
6.8.3 Dispensing of Study Drug ......................................................................................................  18 
6.8.4 Return or Destructi on of Study  Drug ...................................................................................... 18  
7 STUDY PROC EDURES .............................................................................................................. ......... 18 
7.1 INFORMED CONSENT  ........................................................................................................................ 18  
7.2 SCREENING PROCEDURES  ............................................................................................................... 19  
7.3 TREATMENT PERIOD  ........................................................................................................................ 20  
7.4 CONCLUSION OF TREATMENT PERIOD  ............................................................................................... 20  
7.5 POST TREATMENT FOLLOW -UP CALL................................................................................................ 20  
8 METHODS ....................................................................................................................... ..................... 20  
Targeting RV in PAH  Page 3 
Version1  
 
8.1 CMR  IMAGING  .............................................................................................................................. ... 20 
8.1.1 CMR Imaging Protocol .......................................................................................................... . 20 
8.1.2 Analysis of  CMR data .......................................................................................................... .. 21 
8.2 METABOLON /MICRORNA ................................................................................................................. 21  
8.2.1 Procedure ...............................................................................................................................  21 
8.2.2 Analysis of Me tabolon data ....................................................................................................  21 
8.2.3 Analysis of MicroRNA data .................................................................................................... 21 
8.3 HEALTH OUTCOMES ASSESSMENT .................................................................................................... 21  
8.4 LABORATORY DETERMINATIONS  ....................................................................................................... 21  
9 STATISTICAL PLAN .............................................................................................................. .............. 22  
9.1 SAMPLE SIZE DETERMINATION  ......................................................................................................... 22  
9.2 STATISTICAL METHODS  .................................................................................................................... 22  
9.2.1 General Consid erations ........................................................................................................ . 22 
9.2.2 Background Characteristics ................................................................................................... 23 
9.2.3 Efficacy Analysis ............................................................................................................. ....... 23 
9.3 SUBJECT POPULATION (S) FOR ANALYSIS  .......................................................................................... 25  
10 SAFETY AND AD VERSE EVENTS ................................................................................................... 2 5 
10.1 DEFINITIONS  .............................................................................................................................. .... 25 
10.2 RECORDING OF ADVERSE EVENTS  .................................................................................................. 27  
10.3 REPORTING OF SERIOUS ADVERSE EVENTS AND UNANTICIPATED PROBLEMS  ................................... 27  
10.3.1 Investigator reporting: notifying the Penn IRB ..................................................................... 28  
10.3.2 Investigator reporting: No tifying a non- Penn IRB ................................................................ 29  
10.4 MEDICAL MONITORING  ................................................................................................................... 29  
10.5 DATA AND SAFETY MONITORING BOARD  ......................................................................................... 29  
11 DATA HANDLING AND RE CORD KEEPING ................................................................................... 30  
11.1 CONFIDENTIALITY  .......................................................................................................................... 30  
11.2 SOURCE DOCUMENTS  .................................................................................................................... 30  
11.3 DATA MANAGEMENT PLAN ............................................................................................................. 30  
11.4 DATA SHARING PLAN ..................................................................................................................... 30  
11.5 RECORDS RETENTION  .................................................................................................................... 30  
11.6 MANAGEMENT OF INFORMATION FOR MULTI-CENTER RESEARCH  ..................................................... 31  
12 STUDY MONITORING, AUDITI NG, AND INSPEC TING ................................................................... 31  
12.1 STUDY MONITORING PLAN ............................................................................................................. 31  
12.2 REGULATORY DOCUMENTS REVIEWED  ........................................................................................... 31  
12.3 AUDITING AND INSPECTING  ............................................................................................................. 31  
13 ETHICAL CONSIDERATIONS ........................................................................................................... 31  
14 STUDY FI NANCES ................................................................................................................ ............ 32  
14.1 FUNDING SOURCE  ......................................................................................................................... 32  
14.2 CONFLICT OF INTEREST .................................................................................................................. 32  
15 PUBLICATION PLAN .............................................................................................................. .......... 32 
16 REFERE NCES .................................................................................................................... ............... 32  
 
  
Targeting RV in PAH  Page 4 
Version1  
 
 
List of Abbreviations and Definitions 
 
AE Adverse event 
BID Twice a day 
BWH Brigham and Woman’s Hospital 
CMR Cardiovascular MRI 
ECG  Electrocardiography Echo Echocardiography 
HRCT High resolution CT 
IDS Investigational drug service 
LV Left ventricle 
UMD University of Maryland UPenn / Penn University of Pennsylvania 
PAH  Pulmonary hypertension 
PAP Pulmonary artery pressure PCWP Pulmonary capillary wedge pressure 
PO To take orally 
PVR Pulmonary vascular resistance RHC Right heart catheterization  
RV Right ventricle 
RVEF Right ventricle ejection fraction WHO World Health Organization 
6MWT 
eCRF 6 minute walk test 
Electronic case report form 
Evaluable population The evaluable population  is defined as all subjects who have no protocol 
violations that could confound the interp retation of study results, receive at 
least 3 months of the test article. If the subject discontinues due to side 
effect or disease progression, clinical  assessment of disease progression is 
adequate.   
Protocol violation Departure from the protocol that has a significant effect on the subject’s 
rights, safety, or welfare, and/or the integrity of the resultant study data 
(i.e., the sponsor’s ability to use th e data in support of the product). 
Prospective waivers for devi ations from the eligibility criteria will not be 
granted.  
Regulation The term regulation  refers to all applicable regulations, laws, and 
guidelines.  The regulations may be international, national, or local and 
may include but are not limited to the US Code of Federal Regulations; the 
European Clinical Trials Directive; the Good Clinical Practice: Consolidated Guideline (Canada); the International Conference on Harmonisation 
Guideline for Good Clinical Practice; the Pharmaceutical Affairs Law and 
Good Clinical Practice (Japan); the Therapeutic Goods Administration Annotated International Conference on Harmonization Guidelines 
(Australia); and the World Medical Association Declaration of Helsinki: 
Ethical Principles for Medical Research Involving Human Subjects. 
Regulatory agency The term regulatory agency  refers to all health and regulatory agencies 
with oversight responsibility for the study.  These may be international, 
national, or local and may include but are not limited to the Australian 
Therapeutic Goods Administration (T GA); the Canadian Health Products 
and Food Branch (HPFB); the Europe an Medicines Agency (EMEA); the 
Japanese Ministry of Health, Labor,  and Welfare (MHLW); the Japanese 
Pharmaceuticals and Medical Device s Agency (PMDA); the US Food and 
Drug Administration (FDA), etc. 
Sponsor The term sponsor  refers but is not limited to the sponsors listed in the front 
of this document and any contract re search organization that is being used 
for the study. 
Targeting RV in PAH  Page 5 
Version1  
 
Subject A participant in a clinical study.  A subject may be healthy or have a 
disease.  For obtaining informed consent, this term also includes legally 
acceptable representative where applicable. 
Test article For test article accountability, this term applies to such test articles as 
required by this protocol and supplied (shipped) by the sponsor. In this 
study, the  term test article  refers to ranolazine or placebo. 
Woman of childbearing potential A woman of childbearing potential is defined as one who is biologically 
capable of becoming pregnant. This includes women who are using 
contraceptives or whose sexual par tners are either sterile or using 
contraceptives. 
 
 
 
  
Targeting RV in PAH  Page 6 
Version1  
 
1 Study Flowchart  
 Treatment Period  b  
Study Procedure Screening a Interim visit  End of 
Treatment Visit  4 Week Post 
Ranolazine 
Follow-up  
 -4 to 0 1 to 4 months post 
randomization wk26            
(1 month) or 
earlier if endpoint 
occurs  4 weeks post 
end of 
treatment 
visit(+2 weeks)  
Informed consent X    
Demographic data X    
Medical History X    
Cardiac & Pulmonary History X    
Inclusion & exclusion criteria X    
Randomization X    
Plasma samples for Metabolon 
biomarker analysis X  X   
miRNAg X  x  
Clinic visit  X d Xd Xd  
Physical exam/6MWT  X d Xd Xd  
Vital signs  X d Xd Xd  
Borg dyspnea index X d Xd Xd  
WHO functional class X d Xd Xd  
Health outcome        X  X  X   
Medications   Continually (reported every 4 Weeks) X 
Adverse event monitoring   Contin ually (reported every 4 Weeks) X 
ECG  X d Xd Xd  
ECHO  X d  Xd  
CMR  X d  X  
Liver function tests  X d Xd Xd  
CBC with differential  X d Xd Xd  
Chemistry 10  X d Xd Xd  
Coagulation tests  X d Xd Xd  
Uric acid, CRP, ANA, NT-
proBNP, total protein, albumin X d X d X d  
Pregnancy test ( β-HCG)  X d Xd Xd  
Right Heart Catheterization X d    
Drug dispense/reconciliation Xf X  X  
 
Targeting RV in PAH  Page 7 
Version1  
 
Footnotes to Study Flowchart:  
a. The screening evaluation must be completed wi thin 28 days before enrollment (randomization) 
unless otherwise noted.  
b. The treatment period is defined as the period of time from the start of treatment until there is 
evidence of disease progression, or t he subject is withdrawn from treatment 
c. Vital signs include pulse, blood pressure, and O2 sa turation.  Oral, tympanic, axillary, or core 
temperature will also be collected if done per routine clinical care. 
d. Indicates done standard of care . Results from clinic visit/procedu re will be used for research data.  
Procedures and tests not done per standard of care  will not be considered protocol deviations.  
These may be performed as research tests at the discretion of the Investigator (excluding right 
heart catheterization & echo).  Right heart cat heterization is not required, but if performed on 
clinical indication prior to randomization will be used for research data.  
e. Randomization to ranolazine or placebo occurs on Day 1 
f. Drug is dispensed at randomization and 3 m onths later.  Drug reconc iliation is performed at 3 
months clinical visit and at 6 month end of treatment visit.  
  
Targeting RV in PAH  Page 8 
Version1  
 
Study Summary 
Title A randomized, double-blind, placebo controlled, multi-center study to assess 
the effect of ranolazine in subjects with pulmonary hypertension and right 
ventricular dysfunction using cardiovascular MRI  
Short Title Targeting RV in PAH  
Study Design This study is a randomized, double-bli nd, placebo controlled, multi-center 
proof-of-concept study in 10 male or female subjects with pulmonary hypertension (PAH) and RV dysfunction.   Subjects who meet the protocol 
definition of RV dysfun ction (CMR RVEF <45%) will be randomized to 
ranolazine or placebo 2:1.  
 
The study includes a screening period (up to 4 weeks), a treatment period (up 
to 26 weeks 1 month), and a follow-up period (4 weeks).  Subjects in the 
treatment period will be called about ever y 4 weeks to assess any changes in 
health or medications as well as study drug compliance.   
Subjects will receive ranolazine or placebo at 500mg PO BID and after two 
weeks will increase to 1000mg PO BID.  Subjects will continue at 1000mg BID for the duration of the study.  Subjects with adverse reactions that are difficult 
to tolerate will be down titrated to 500mg BID. Subjects on moderate CYP3A 
inhibitors will be limited to 500mg BID. 
At baseline (week 0), interim (1 to 4 months post randomization) and the 
conclusion of the treatment period (w eek 26) subjects will be assessed for 
functional class, 6- MWD, and HEALTH OUTCOME based on SF-36 tool. 
Peripheral blood will be obtained for metabolic profiling at baseline and the 
conclusion of the treatment period.  Cardiovascular MRI (CMR) will be performed at baseline and the conclusion  of the treatment period.  Baseline 
CMR may be done per standard of care or as a research scan.  
Study Center(s) Multicenter, 3 sites: 
University of Pennsylvania  Brigham and Women’s Hospital  
University of Maryland 
Primary Objective 1. To assess changes in metabolism and RV function before and after 
treatment with ranolazine compared to placebo  
2. To demonstrate that treatment wi th ranolazine improves RV energetic 
and contractility in the subjects with persistent RV dysfunction as 
measured by imaging 
Exploratory Objective To evaluate the effects of ranolazine in subjects with PAH on stable 
background therapy and persis tent RV dysfunction. 
Number of Subjects Up to 10 subj ects will participate in this study  
Diagnosis and Main 
Inclusion Criteria Planned enrollment will include NYHA class II/III/IV PAH subj ects. Subjects 
must be on stable PH therapy and have a clinical right heart catheterization 
(RHC) which documents a mean PAP ≥25 mmHg, PVR >3WU (>240 dyne ⋅
sec/cm5), and pulmonary capillary wedge pressure (PCWP) or LV end 
diastolic pressure ≤15 mmHg.  
Study Product, Dose, 
Route, Regimen, 
Duration Subjects will receive ranolazine or placebo at 500mg PO BID and after two 
weeks will increase to 1000mg PO BID and continue for a total of 26 weeks 1 
month.   
Reference therapy Placebo    
Statistical 
Methodology This trial is designed to understand the impact of ranolazine on RV function. 
We’ll be examining different imaging markers as conti nuous variables 
comparing the difference pre and post drug treatment. 
Targeting RV in PAH  Page 9 
Version1  
 
 
2 Introduction 
This document is a protocol for a human research st udy. This study is to be conducted according to US 
and international standards of Good Clinical Practice (FDA Title 21 part 312 and International Conference 
on Harmonization guidelines), applicable government r egulations and Institutional research policies and 
procedures.  
2.1 Background 
During the progression of PAH, many of the mo lecular mechanisms that drive transition from 
compensated hypertrophy to dilatation and failure in  the RV remain enigmatic. Much of our understanding 
is based on cell culture and animal models or is extra polated from data of left vent ricular (LV) dysfunction. 
Reflected by re-expression of fetal-type contractile proteins, angiogenic rarefaction, and alterations in 
calcium handling, numerous molecular signaling pathways  are thought to be activated in RV dysfunction, 
leading to increased levels of reactive oxygen (R OS) or nitrogen (RNS) species, inflammation, RV 
ischemia, cardiomyocyte apoptosis, and decr eased contractility, as recently reviewed1. However, further 
mechanistic insight into the progression of RV dysfunction has been hampered by an inability to obtain 
RV specimens in sufficient quantity for molecular anal ysis from subjects with progressive PAH and RV 
failure. Moreover, substantial differences exist among animal models of PAH and human PAH2, making 
animal-derived insights suboptimal and sometime s misleading regarding PAH and RV dysfunction in 
human subject populations. Thus, the development of ta rgeted therapeutics in RV failure has been slow. 
 More recently, animal modeling of RVH and RV failure in PAH has revealed a substantial down-regulation 
of mitochondrial oxidative metabolism in favor of glycolysis (GL). The molecular mechanisms controlling 
this metabolic shift in the RV are unclear
3, but, in part, may involve alterations of potassium channel 
function4-6. Importantly, in rodents with experimental PAH7, 8 or chronic RV overload9, RVH, RV electrical 
remodeling, and RV dysfunction can be normalized with dichloroacetate (DCA), an inhibitor of pyruvate 
dehydrogenase kinase (PDK) which in turn activates pyruvate dehydrogenase (PDH) to favor oxidative 
metabolism. These findings suggest that alteration s in mitochondrial function, metabolism, and energy 
substrate utilization are keys to understanding the progression to RV failure. Observational human data 
through PET corroborate these findings by reveali ng increased uptake of glucose in PAH-dependent RV 
dysfunction10, 11. Yet, a true causative mechanism of metabolic  dysregulation for RV dysfunction in human 
PAH has not been established. Furthermore, data are spar se regarding the efficacy and safety profile of 
DCA in humans, and it is currently not an FDA-approved medication. Alternatively, ranolazine, which is 
currently used for refractory myocardial ischemia12, 13, also activates PDH14-16 as well as inhibits fatty acid 
oxidation, sodium currents, and sodium-dependent calcium overload, as previously reviewed17. Recently, 
in a rodent model of RVH, ranolazine was reported to successfully reverse metabolic dysfunction and 
improve cardiac output and exercise capacity16. Thus, ranolazine may have substantial therapeutic 
potential in RV dysfunction and PAH, and could be read ily “re-purposed” as an already FDA-approved 
medication.  
 
In addition to PDH, other metabolic factors likely exist that are dy sregulated in RV failure and primarily 
drive pathogenesis. Historically, RV failure had been described as a stereotyped response to 
hemodynamic overload. More recent large patient cohort data suggests that RV, independently from 
PAP, predicts mortality18. Thus, a recent hypothesis suggests that individual genetic differences 
dysregulate cardiomyocyte function and, in doing so, pr edispose to RV failure in humans, control patient-
specific manifestations of diseas e, and thus would represent key diagnostic markers and therapeutic 
targets. While deficiencies in BMPR219-23 or ALK124 predispose to the development of PAH and 
theoretically could affect RV function, such mutati ons are unlikely to be the only genetic factors involved. 
In fact, multiple key metabolic regulatory factors have been found to be altered in RV failure, any one of 
which could contribute to individual predisposition to RV failure. Based on their established functions in 
left ventricular injury and metabolism25 and known alterations in right ventricular failure26, changes in 
microRNA (miRNA) expr ession, which are small, non-coding  RNA that negatively regulate gene 
expression, could also underlie such a predisposition to metabolic dysfunction of the RV. Furthermore, 
similar to secreted metabolites, miRNA c ould be released from injured myocardium27 and could thus 
Targeting RV in PAH  Page 10 
Version1  
 
serve as disease biomarkers. Howe ver, the lack of a clear familial pattern of inheritance of RV 
dysfunction, accompanied by the rela tively small PAH patient population,  limits the utility of large scale 
genomic sequencing or genome wide association study al one to identify the existence of these factors.  
 
2.2 Investigational Agent  
2.2.1 Description 
Ranexa™ (ranolazine) is available as an ex tended-release tablet for oral administration. 
Ranolazine is a racemic mixture and chemic ally described as 1-piperazineacetamide, N -(2,6-
dimethylphenyl)-4-[2-hydroxy-3-(2-methoxyphenoxy)pr opyl]-, (±)-. It has an empirical formula of 
C24H33N3O4, a molecular weight of 427.54 g/mole , and the following structural formula: 
 
Ranolazine is a white to off-white solid. Ranolazine is  soluble in dichloromethane and methanol; sparingly 
soluble in tetrahydrofuran, ethanol, acetonitrile, and aceton e; slightly soluble in ethyl acetate, isopropanol, 
toluene, and ethyl ether; and very slightly soluble in water. 
Ranexa is available for oral administration as film-c oated, extended-release tabl ets containing 500 mg of 
ranolazine. Inactive ingredients of the 500 mg tabl et include carnauba wax, hypromellose, magnesium 
stearate, methacrylic acid  copolymer (Type C), microcrystalline ce llulose, polyethylene glycol, polysorbate 
80, sodium hydroxide, titanium dioxide, and FD&C Yellow #6 Lake. 
2.2.2 Mechanism of Action 
Ranexa has antianginal and anti-ischemic effects that do not depend upon reductions in heart rate or 
blood pressure. The mechanism of action of ranola zine is unknown. It does not increase the rate-
pressure product, a measure of myoc ardial work, at maximal exercise. 
2.2.3 Pharmacokinetics 
Ranolazine is extensively metabolized in gut and liver and its absorption is highly variable. For example, 
at a dose of 1000 mg b.i.d., the mean steady state C max was 2569 ng/mL; 95% of C max values were 
between 420 and 6080 ng/mL. The pharmacokinetics of t he (+) R and (-) S-enantiomers of ranolazine are 
similar in healthy volunteers. The apparent terminal  half-life of ranolazine is 7 hours. Steady-state is 
generally achieved within 3 days of b.i.d. dosing with  Ranexa. At steady-state over the dose range 500 to 
1000 mg b.i.d., C max and AUC 0-τ increase slightly more than proporti onally to dose, 2.2- and 2.4-fold, 
respectively. With twice daily dosing, the peak/trough ratio of the ranolazine plasma concentration is 1.6 
to 3.0. 
2.2.4 Absorption and Distribution 
After oral administration of Ranexa peak plasma conc entrations of ranolazine are reached between 2 and 
5 hours. After oral administration of 14C-ranolazine as a solution, 73% of the dose is systemically 
available as ranolazine or metabolites. The bioavailabilit y of ranolazine from Ranexa relative to that from 
a solution of ranolazine is 76%. Because ranolazine is a substrate of P-glycoprotein (P-gp), inhibitors of 
P-gp may increase the absorption of ranolazine. 
 

Targeting RV in PAH  Page 11 
Version1  
 
Food (high fat breakfast) has no important effect on the C max and AUC of ranolazine. Therefore, Ranexa 
may be taken without regard to meals. Over the co ncentration range of 0.25 to 10 µg/mL, ranolazine is 
approximately 62% bound to human plasma proteins. 
2.2.5 Metabolism and Excretion 
Following a single oral dose of ranolazine solution, approximately 75% of the dos e is excreted in urine 
and 25% in feces. Ranolazine is metabolized rapidly and extensively in the liver and intestine; less than 
5% is excreted unchanged in urine and feces. The ph armacologic activity of the metabolites has not been 
well characterized. After dosing to steady-state wi th 500 mg to 1500 mg b.i.d., the four most abundant 
metabolites in plasma have AUC values ranging from  about 5 to 33% that of ranolazine, and display 
apparent half-lives ranging from 6 to 22 hours. Ranolazine is metabolized mainly by CYP3A and to a 
lesser extent by CYP2D6. 
 
2.3 Preclinical Data 
In rodents with experimental PAH7, 8 or chronic RV overload9, RVH, RV electrical remodeling, and RV 
dysfunction can be normalized with dichloroacetate (D CA), an inhibitor of pyruvate dehydrogenase kinase 
(PDK) which in turn activates pyruvate dehydroge nase (PDH) to favor oxid ative metabolism. These 
findings suggest that alterations in mitochondrial function, metabolism, and energy substrate utilization 
are keys to understanding the progression to RV failure.  Ranolazine, which is currently used for 
refractory myocardial ischemia12, 13, also activates PDH14-16 as well as inhibits fatty acid oxidation, sodium 
currents, and sodium-dependent calcium overload17. Recently, in a rodent model of RVH, ranolazine was 
reported to successfully reverse metabolic dysf unction and improve cardiac output and exercise 
capacity16.  
 
2.4 Clinical Data to Date 
Ranolazine has been evaluated in patients with chronic angina who remained symptomatic despite 
treatment with the maximum dose of an antianginal agent. In the ERICA 36(Efficacy of Ranolazine In 
Chronic Angina) trial, 565 patients were randomized to receive an initial dose of ranolazine 500 mg b.i.d. 
or placebo for 1 week, followed by 6 weeks of treatm ent with ranolazine 1000 mg b.i.d. or placebo, in 
addition to concomitant treatment with amlodipine 10 mg q.d. In addition, 45% of the study population 
also received long acting nitrates. Sublingual nitrat es were used as needed to treat angina episodes. 
Statistically significant dec reases in angina attack frequency (p = 0.028) and nitroglycerin use (p = 0.014) 
were observed with ranolazine compared to place bo. These treatment effect s appeared consistent across 
age and use of long acting nitrates.  
CARISA37 was a study in 823 chronic angina patients rand omized to receive 12 weeks of treatment with 
twice-daily ranolazine 750 mg, 1000 mg, or placebo w ho also continued on daily doses of atenolol 50 mg, 
amlodipine 5 mg, or diltiazem CD 180 mg. Sublingual ni trates were used in this study as needed. In this 
trial, statistically significant (p < 0.05) increases in  modified Bruce treadmill exercise duration and time to 
angina were observed for each ranolazine dose versus  placebo, at both trough (12 hours after dosing) 
and peak (4 hours after dosing) plasma levels, with minimal effects on blood pressure and heart rate. 
Exercise treadmill results showed no incr ease in effect on exercise at t he 1000 mg dose compared to the 
750 mg dose. 
There is no clinical data on the use of ranolazine in this study patient populati on. However, there is a 
clinical trial ([STUDY_ID_REMOVED]) ongoing.  The group of PAH subjects targeted in the cited trial must have 
angina or angina equivalent, and the trial primarily focuses on exercise capacity and hemodynamic 
assessment. The cited trial has a durat ion of 3 months with estimated enrollment is 25 subjects without a 
control group and is a single center open label study. 
 
Targeting RV in PAH  Page 12 
Version1  
 
2.5 Dose Rationale and Risk/Benefits 
 
Subjects will receive ranolazine or placebo at 500mg PO BID and after two weeks will increase to 
1000mg PO BID and continue for a total of 26 weeks 1 month.   The most common reported adverse 
reactions during treatment with ranolazine (>4% and more common than with placebo) were dizziness 
(6.2%), headache (5.5%), constipati on (4.5%), and nausea (4.4%).   Dizziness appeared to be dose 
related in clinical trials.  Subjects with persistent adverse reactions will be down titrated to 500mg BID. 
Subjects on moderate CYP3A inhibitors will be limited to 500mg BID.  For detailed safety information on ranolazine, refer to the most recent version from  the manufacture website (Gilead).  The route of 
administration, dosage, and dosage regimen are per manufacturer label for chronic angina.  1000 mg 
twice a day is the maximum tolerated dose. The do sage period is longer than what has been tested for 
angina because we hypothesize that ranolazine’s effect on RV metabolism will result in improvement in 
RV function and therefore patient symptoms will take longer than angina symptom relief due to time 
required for RV remodeling.  The maximum tolerated dose is targeted in order to derive the maximum benefit if there is any benefit to t he patients. The risks of exposure as  related to adverse reactions is 
uncommon and are reasonable given that RV is a nove l therapeutic target and current PAH therapies do 
not address RV dysfunction.    
3 Study Objectives 
 
Primary Objectives:  
 
1. To demonstrate that treatment with ranolazi ne improves RV function in the subjects with 
persistent RV dysfunction as measured by cardiac MRI 
 Exploratory Objectives: 
 
1. To evaluate the clinical effect of ranolazine in subjects with PAH on stable background therapy 
and persistent RV dysfunction, including 6MWT, WHO class, and clinical progression of disease.  
2. To evaluated novel cardiac MRI markers such as changes in 4D flow and T1mapping.  
3. To evaluate changes in metabolism with r anolazine as measured by serum metabolites 
4. To evaluated changes in microRNA.  
5. To evaluate changes in qualit y of life using questionnaire.  
 
4 Study Design 
4.1 General Design 
This study is a randomized, double-blind, placebo cont rolled, multi-center proof -of-concept study in 10 
male or female subjects with pulmonary hypertensio n (PAH) and RV dysfunction.  Subjects who meet the 
protocol definition of RV dysfunction (CMR RVEF <45%) will be randomized to ranolazine or placebo 2:1.  
 
The study includes a screening period (up to 4 weeks), a treatment period (up to 26weeks 1 month), and 
a follow-up period (4 weeks).  Subj ects in the treatment period will be called about every 4 weeks to 
assess any changes in health or medications as well as study drug compliance.   
Subjects will receive ranolazine or placebo at 500mg PO BID and after two weeks will increase to 
1000mg PO BID.  Subjects will continue at 1000mg BID for the duration of the study.  Subjects with 
adverse reactions that are difficult to tolerate will be down titrated to 500mg BI D. Subjects on moderate 
CYP3A inhibitors will be limited to 500mg BID.  
At baseline (week 0), interim (1 to 4 months post randomization) and the conclusion of the treatment 
period (week 26 2) subjects will be assessed for functional cla ss, 6MWT, and HEALTH OUTCOME 
based on SF-36 tool. Peripheral blood will be obtained for metabolic profiling and microRNA at baseline 
Targeting RV in PAH  Page 13 
Version1  
 
and the conclusion of the treatment period.  Cardiovascular MRI (CMR) will be performed at baseline and 
the conclusion of the treatment period.   
4.2 Primary Study Endpoints 
 
1. Change in RVEF using CMR in subjects with pulm onary hypertension before and after treatment with 
ranolazine  
 
4.3 Exploratory Endpoints 
4.3.1 Outcomes 
Number and percentage of subjects with high risk pr ofile at Week 26. Patients with high risk profile are 
defined as patients with clinical worsening events or  lack of clinical improvement at Week 26.  
 
 Clinical improvement is defined as an increase in 6MWD >or= 15% or more from baseline AND 
an improvement (decrease) in functional class by at least 1 class by end of treatment visit, week 
26. 
 
 Clinical worsening event (adjudicated), as def ined by at least one of the events listed below: 
         Death (all causes)  
         Hospitalization due to worsening PAH defined as: 
o Non-elective hospitalization lasting at leas t 24 hours in duration caused by clinical 
conditions directly related to PAH and/or right heart failure; or 
o Lung or heart / lung transplantation; or 
o Atrial septostomy 
         Initiation of a prostacyclin for the treatment of worsening PAH  
         Disease progression (all criteria required): 
o A decrease in 6MWD of at l east 15% from Baseline (or too ill to walk) directly related 
to PAH progression with other co-morbi dities ruled out, confirmed by 2 6MWTs 
performed on different days. 
o Worsening of PAH symptoms, which must include either 
 An increase in functional class or 
 New onset of at least one symptom what did not respond to oral diuretic therapy 
(syncope, near syncope, chest pain, chest discomfort, orthopnea and dizziness)*   
 
4.3.2 CMR 
Additional exploratory analyses will be performed in the CMR imaging such as 4D flow and T1mapping. 
4.3.3 Metabolism  
Comparisons will also be made in chan ges of metabolites in subjects.  
4.3.4 MicroRNA  
Comparisons will also be made in changes of microRNA in subjects.  
4.3.5 Health outcome SF-36 
The objective is to assess the improvement in qualit y of life of the subjects after being treated with 
ranolazine. SF-36 is a short-form health survey with 36 questions.  The endpoint is the 8-scale profile of 
functional health and well-being scores.   
Targeting RV in PAH  Page 14 
Version1  
 
 
5 Subject Selection and Withdrawal 
5.1 Inclusion Criteria 
 
1) Have a current diagnosis of symptomatic PAH based on one of the following criteria: 
a) Idiopathic pulmonary arterial hypertension 
b) Familial pulmonary arterial hypertension c) PAH associated with connective tissue disease 
i) Systemic sclerosis 
ii) CREST iii) Mixed connective tissue disease 
iv) Systemic lupus erythematosus 
d) CTEPH-nonsurgical/distal vessel disease or CT EPH patients who are reluctant to go to surgery 
within a 6-month period an d are willing to participate 
e) Simple congenital such as repaired ASD/VSD or unrepaired small ASD/VSD with persistent and 
out of proportion PAH 
f) Group 3 patients who have a component of PAH and do not meet exclusion criteria (5) in 5.2.  
g) PAH caused by conditions affect the veins and small vessels of the lungs, sickle cell disease.  
h) Group 5 PH such as polycythemia vera, essential thrombocythemia, sarcoido sis, or vasculitis, or 
metabolic disorder.  Sarcoid with known cardia c involvement (LV and/or RV) will be excluded.  
2) WHO functional class II, III, or IV 3) Age >18 and < 80 years of age  
4) For incident cases a right heart catheterization perf ormed within 100-days prior to enrollment (defined 
as randomization) that shows the following (prevalent  cases require a historical RHC within the past 
60-months): 
a) Mean pulmonary artery pressure >25 mmHg at rest 
b) Pulmonary capillary wedge pressure or left vent ricular end diastolic pressure < 15 mmHg. If the 
PCWP is >15 but < 20 mmHg then the trans pulmonary Gradient must be greater than 25. 
c) Pulmonary vascular re sistance > 3 mmHg/L/min 
5) CMR RVEF < 45% obtained from a CM R  done within 28 days of enrollment  
6) 6-minute walk test distance > 50 mete rs within 90 days prior to enrollment  
7) No dual up-front therapies permitted for Stratum I (incident) patients.   
8) No addition or discontinuation of PAH specific medication within 90 days and no change in PAH 
specific medication dose within 28 days prior to bas eline imaging procedures. Note:  Adjustment of 
diuretic dose (increase or decrease of 100% or less) is permissible. Switches from same class of 
medication may only require a stable dose 28 days prior to baseline imaging procedures at the 
discretion of the Investigator.   
9) Subjects must be capable of giving informed consent 
 
Targeting RV in PAH  Page 15 
Version1  
 
5.2 Exclusion Criteria 
1) Previous treatment with or prior sens itivity to any formulation of ranolazine. 
2) Any family history of QTc prolongation, congenita l long QT syndrome, or receiving drugs that prolong 
the QTc interval such as Class Ia (e.g., quinidine ) or Class III (e.g., dofetilide, sotalol, amiodarone) 
antiarrhythmic agents, erythromycin, and certain antipsychotics (e.g. thioridazine, ziprasidone). 
3) For patients who have a prolonged QTc of >480 ms that is not due to the above exclusion #2 AND an 
increased QRS duration of >120 ms, QTrr,qrs formula38 will be used to calculate an adjusted QTc. 
Patient will be excluded if an adjusted QTc is >460 ms. 
4) Subject receiving IV inotropes within 2 weeks prior to the baseline imaging procedures 
5) Parenchymal lung disease based on pulmonary functi on testing within the past 12-months prior to 
baseline imaging procedures showing any of the following: 
a) Total lung capacity < 50% of predicted and a HRCT  that does not demonstrate clinically severe 
interstitial lung disease based on the discretion of the Investigator 
b) FEV1/FVC < 50% 
6) Subjects currently on a strong CYP3A inhibitor or inducer, or hepatic enzymes > 3x ULN, or moderate 
to severe liver disease 
7) Portal hypertension associated with either ci rrhotic or non-cirrhotic ch ronic liver disease.  
8) Left sided heart disease including any of the following: 
a) Moderate or greater aortic or mitral valve disease  
a) Any LV cardiomyopathy (including but not lim ited to restrictive, amyloid, hypertrophic) 
b) Left ventricular systolic dy sfunction defined as an ejection fr action < 50% by echocardiography 
c) Symptomatic coronary artery disease 
9) Uncontrolled systemic hypert ension (systolic BP > 160 mmHg or diastolic >100 mmHg) with or 
without treatment.  
10) Inability to perform a 6-minute walk test because of a mechanical problem such  as arthritis, morbid 
obesity, or musculoskeletal problem 
11) The subject has the presence, or history, of ma lignancy that required significant medical intervention 
within the preceding 3 months and/or is likely to re sult in death within the next 2 years (exception of 
basal cell or non-metastatic squamous cell carcinoma of the skin, and carcinoma in-situ of the cervix).   
12) The receipt of any investigational medication with in 14 days prior to baseline imaging or the need for 
another investigational drug durin g the course of this study. Note: Subjects on an investigational 
medication may enroll if they meet inclusion crit eria #8 and they are anticipated to remain on the 
investigational medication for the duration of the trial (26 weeks).  
13) Pregnancy or lactation: Wo men of childbearing potential and no n-vasectomized men must agree to 
use a barrier method of contraception duri ng screening and for the entire Study Period 
14) ICD, Pacemaker, hazardous metallic impl ants or any other contraindication to MRI. 
15) Severe anxiety or claustrophobia prohibiting completion of cardiac MRI. 
16) Psychiatric disorder that compromise s the ability to provide informed consent. 
 
5.3 Early Withdrawal of Subjects 
The criteria for enrollment must be followed explicitly.  If a subject who does not meet enrollment criteria 
is inadvertently enrolled, that subject should be di scontinued from the study.  A subject may voluntarily 
discontinue participation in this study at any time.  The investigator may also, at his or her discretion, 
Targeting RV in PAH  Page 16 
Version1  
 
discontinue the subject from participating in this study at any time.  If a subject is prematurely 
discontinued from participation in the study for any re ason, at any time, at either the investigator’s 
discretion or the subject’s request, an effort must be made to document the reason(s) why a subject fails 
to return to the study clinic for ne cessary visits or is discontinued from the study.  The primary reason for 
discontinuing participation in the st udy must be stated in the CRF and ma y include, but is not limited to, 
one of the following: 
 
 Progressive disease as determined by the investigator  
 Use of unapproved concomitant medications (initiati on of a strong CYP3A inhibitor or inducer without 
any alternative therapies; initiation of a moderate  CYP3A inhibitor would warrant dose reduction), 
 Occurrence of intolerable AEs 
 Withdrawal of consent by subject 
 Noncompliance with protocol, e.g., the subj ect fails to appear at one or more visits 
 Development of an intercurrent illness, injury, or  medical condition likely to interfere with subject 
safety, the overall assessment, or the required administration of study medication 
 Pregnancy 
 Development of any condition for which the invest igator feels treatment withdrawal is justified 
 Termination of the study  
When a subject discontinues or is wi thdrawn, the investigator  will perform the proce dures indicated for the 
end of treatment visit when possible.  
Follow-up information will be obtained for subjects who discontinue the treatment  phase of the study.  
See the flowcharts for procedures to be perfo rmed at end of treatment and follow-up visits. 
Subjects withdrawn from the study will not be repl aced, regardless of t he reason for withdrawal. 
An effort must be made to determine why a subject fails to return for the necessary visits or is dropped 
from the study.  This information will be recorded in the medical record and on the subject’s electronic 
CRF (eCRF). 
 
6 Study Drug  
6.1 Description 
Ranolazine is a racemic mixture and chemical ly described as 1-piperazineacetamide, N -(2,6-
dimethylphenyl)-4-[2-hydroxy-3-(2-methoxyphenoxy)pr opyl]-, (±)-. It has an empirical formula of 
C24H33N3O4, a molecular weight of 427.54 g/mole. Ranexa is available for oral administration as film-
coated, extended-release tablets cont aining 500 mg of ranolazine.  
6.2 Treatment Regimen 
All subjects will receive ranolazine or placebo at 5 00mg PO BID and after two weeks will increase to 
1000mg PO BID.  Subjects will continue at 1000mg BID for the duration of the treatment period (26 
weeks).  Subjects with persistent adverse reacti ons will be down titrated to 500mg BID. Subjects on 
moderate CYP3A inhibitors will be limited to 500mg BID.  
6.3 Method for Assigning Subjects to Treatment Groups 
This is a double blind study.  Subjects will be random ized in a 2:1 fashion to ranolazine or placebo by the 
University of Pennsylvania Investi gational Drug Service (IDS).   
 
Targeting RV in PAH  Page 17 
Version1  
 
A subject number will be assigned to an individual at the screening visit. Randomization of the subject will 
proceed through the use of a randomization table at Penn IDS. The Investigational Drug Service will 
prepare a randomization table using random blocks of 3, at a 2:1 ratio of active to placebo (this is a 
continuation of the study which randomized 14 subjects  that was sponsored by CMREF).  The table will 
be computer-generated prior to the st art of the trial and maintained securely within the Investigational 
Drug Service (IDS), which is not accessible to the re st of the study team.  Subjects will be assigned to 
treatment in sequential order (lowest to highest).   For emergency unmasking, the IDS will upload the 
randomization table into a secure web portal and issue an account for the study principal 
investigator.  The account will per mit access from any internet-en abled computer and will collect 
information on the reason for unmasking (such as whether there is a serious adverse event) before revealing the treatment assignment for one individual  subject.  All use of the emergency unmasking 
system is logged and reviewed periodically by IDS pers onnel.  If the PI is to remain blinded, the IDS may 
contact treating physicians directly to disclose treatment assignment.
 
After a subject is screened and determined to be eligible for the study, the site personnel (the investigator 
or his/her designee) will contact Penn IDS and get  a randomization number. The randomization number 
and the date the randomization number is assigned w ill be recorded in the eCRF. Once randomization 
numbers and registration numbers have been assigned, they cannot be reassigned.  
When a subject discontinues treatment, the invest igator or his or her designee will enter date of 
discontinuation on the eCRF and the date when the last dos e of test article was received by the subject.  
6.4 Preparation, Packaging and Administration of Study Drug 
Ranolazine and placebo will be shipped directly from G ilead to Penn’s Investigational Drug Service (IDS). 
IDS will be coordinating the random ization process. The IDS will pa ckage blinded study medications 
according to the Hospital of the University of P ennsylvania’s Pharmacy Policy and Procedures. Labeling 
will be done by the IDS, and each packet will incl ude the subject’s registra tion number, name, date 
dispensed, storage conditions and directions for use.  Penn IDS will ship to research pharmacy or 
investigator at each institution once the subject is  enrolled and randomization procedure is performed.  
6.5 Subject Compliance Monitoring 
At each study visit, compliance with study drug will be reinforced. When st udy drug is returned, 
compliance will be assessed by pill count. Study medi cation dispensed or returned to IDS must be 
recorded for Drug Accountability and Reconciliation at each visit. Study drug bottles will be required to be 
returned at applicable visits throughout the study.  
6.6 Prior and Concomitant Therapy 
Use of medications not exclud ed in the entry criteria will be permitted at the discretion of the investigator.  
Any medication, including over-the-counter medicati ons, used during the cour se of the study will be 
documented.    
Eligible subjects may be receiving one of the following treatment regimens at screening:  
 
 Monotherapy with an endothelin receptor antagoni st (ERA: e.g., ambrisentan, or bosentan), a 
phosphodiesterase type-5 inhibitor (PDE5i: e.g ., sildenafil, tadalafil),  a parenteral prostanoid 
(intravenous [iv] epoprostenol, iv or subcutaneous Treprostinil), or an inhaled prostanoid (inhaled 
iloprost or treprostinil) that is approved for the treatment of PAH   
 Patient might be on chronic therapy for PAH including but not limited to digoxin and/or  
amlodipine.   
 Combination therapy with eligible PAH treatment s (any combination of two or three of ERA, 
PDE5i, or prostanoid).  
 
 Other new PAH specific therapies at  the discretion of the Investigator 
Targeting RV in PAH  Page 18 
Version1  
 
6.7 Blinding of Study Drug 
This is a double blind study. Only the pharmacy at t he University of Pennsylvania IDS will know if the 
subject is receiving active or placebo ranolazine.  Neither the study investigat ors nor the rest of the 
research team will know wh ich subjects receive active  versus placebo until the data base is locked.   
 
Unblinding a subject's treatment assignment may be done only for reasons related to subject safety. All 
efforts will be made to keep the investigator team blinded, such as having IDS send the unblinding information directly to the treating physician without in volving the Investigator. If the investigator is the 
treating physician, then they will be involved in the un blinding.  Unblinding reasons, date, and time will be 
documented in the subject research record. The DSMB may also request for unblinding to occur through concerns over subject safety. 
 
6.8 Receiving, Storage, Dispensing and Return 
6.8.1 Receipt of Drug Supplies 
Upon receipt of the of the study  treatment supplies, an inventory must be performed and a drug receipt 
log filled out and signed by the person accepting the shipment.  It is important that the designated study 
staff counts and verifies that the shipment contains all the items noted in the shipment inventory.  Any 
damaged or unusable study drug in a given shipment (active drug or comparator) will be documented in 
the study files.  The investigator  must notify study sponsor of any damaged or unusable study treatments 
that were supplied to the investigator’s site. 
 
6.8.2 Storage 
The investigational pharmacist at the IDS will ensure that all study drugs is stored in a secured area, 
under recommended storage conditions and in accordance  with applicable regulatory requirements, and 
will be dispensed by qualified staff members. The pharmacist will maintain accurate records regarding 
study drug administration and return. 
 
6.8.3 Dispensing of Study Drug 
The IDS service will maintain accurate logs of st udy drug dispensing, and will conduct regular drug 
reconciliation checks to document dr ug assigned, drug consumed, and dr ug remaining. This reconciliation 
will be logged on the drug reconciliation form , and signed and dated by the service.   
 
6.8.4 Return or Destruction of Study Drug 
At the completion of the study, there will be a final reconciliation of drug shi pped, drug consumed, and 
drug remaining.  This reconciliation will be logged on the drug reconciliation form, signed and dated.  Any 
discrepancies noted will be investigated, resolved, and documented prior to return or destruction of 
unused study drug.  Drug destroyed on site  will be documented in the study files. 
 
7 Study Procedures 
7.1 Informed Consent 
The investigator will provide for the protection of the subjects by following all applicable regulations.  
These regulations are available upon request from t he sponsor.  The sponsor and IRB must review the 
informed consent form used during the informed consent process, and it must be available for inspection.   
Before any procedures specified in this protocol are performed *, a subject must: 
 Be informed of all pertinent aspects of the study and all elements of informed consent.  
 Be given time to ask questions and time to consider the decision to participate. 
Targeting RV in PAH  Page 19 
Version1  
 
 Voluntarily agree to participate in the study.  
 Sign and date an IRB/IEC-approved informed consent form. 
 
(* If a procedure is done routinely as standard of ca re, then it is not study-specific, and it may be done 
before the consent is signed.) 
7.2 Screening Procedures 
The following procedures will be performed during the screening visit.  The screening visit can be one 
visit, or several visits occurring over 28 days.  A ll assessments must be completed within 28 days before 
enrollment (defined as randomization) unless otherwise noted.    The following must be done within 90 days prior to enrollment: 
 Informed consent: a signed and dated institutional  review board (IRB) or independent ethics 
committee (IEC) approved ICF. This has to be clearly documented in the subject’s source 
documents.   
 Demography: including gender, date of birth, and race 
 6MWD  
 Borg dyspnea index 
 Medical history: including collection of t he subject’s past and present medical history 
 The following must be done within 28 days prior to enrollment: 
 Prior and current medications  
 HEALTH OUTCOMESF-36 assessment  
 Screening CMR. Note: CMR may be repeated 1 additional time if needed due to data 
quality. [note: Urine pregnancy test will be done at CMR for women of childbearing potential] 
 Collection of fasting blood sample for metabolic profiling & LFTs 
 ECG  
 
The most recent data will be  collected for the following: 
 Baseline labs will incl ude CBC, Chem10, LFTs, ANA, CRP, ur ic acid, total protein, albumin, 
Pro-NT BNP and coagulation analysis  
 Physical examination  
 ECG 
 Echocardiography  
 
Adverse events will be recorded starting from the baseline CMR or randomization if CMR is done 
clinically.    
If the subject has undergone a clinical CMR accordin g to institutional standar ds within 30 days of the 
randomization then the clinical scan may be used as  the screening scan for qualification. Additional 
imaging sequences will be performed in an additional resear ch MRI. If a clinical CMR is not planned, the 
subject will undergo a baseline research CMR as part of this protocol.  
Targeting RV in PAH  Page 20 
Version1  
 
7.3 Treatment Period 
On Study Day 1 subjects will be randomized 2:1 to r anolazine or placebo.  After randomization, subjects 
should initiate treatment within 14 business days at t he investigator’s site and will continue treatment for 
26 weeks ( 1 month). The “treatment period” is defined as the period from the start of treatment until end 
of treatment or end of study page is completed.   
The following may be done during the treatment period  as clinical standard of care clinic visits: 
  
 Physical examination  at 1 to 4 months post randomization   
 Borg dyspnea score and 6MWD at 1 to 4 months post randomization 
 WHO and HEALTH OUTCOME assessment at  1 to 4 months post randomization 
 Laboratory testing at 1 to 4 months post randomization  
 Recording of AEs and concomitant medications in source documents will be done regularly 
throughout the treatment period  
 
7.4 Conclusion of Treatment Period 
Subjects will complete the treatment period at week  26 (or earlier if endpoint criteria are met) (  1 month) 
and will come in for the following procedures: 
 
 Physical examination, including weight, and assessment of the Borg dyspnea score 
 Vital signs  
 6MWD 
 WHO and HEALTH OUTCOME 
 ECG  
 Laboratory testing 
 AE and concomitant medication assessment 
 Research CMR. Note: CMR may be repeated 1 additional time if needed due to data quality. 
 
Subjects who meet endpoint criteria must have final imaging procedures done as close to the endpoint 
date as possible, which may be prior to week 26.   
 
7.5 Post Treatment Follow-Up Call 
Subjects will be called about 4 weeks after stoppi ng study drug to document changes in health and 
medications only.   
 
8 Methods  
8.1 CMR Imaging  
8.1.1 CMR Imaging Protocol 
CMR will be performed on the clinic al 1.5T MR systems (Avanto, Siemens, Erlangen, Germany). Cine 
images of the short axis, 4-chamber, 2 chamber RV inflow, and oblique coronal RV views will be 
obtained. Phase contrast velocity images will be  obtained including 4D flow.  Mapping sequences for 
tissue characterization  will be acquired.  
Targeting RV in PAH  Page 21 
Version1  
 
  
8.1.2 Analysis of CMR data 
From the cine images, RV and LV ventricular si ze, volumes, mass, and function are analyzed using 
Qmass (Medis) and then indexed to body surface area.   Phase contrast images will be processed using 
software tools.  
 
8.2 Metabolon/MicroRNA 
8.2.1 Procedure 
Peripheral blood at the baseline and end of treatment visit will be obtained from subjects to send for 
Metabolon analysis.  For the subjects who have a c linically indicated right heart catheterization during 
screening, plasma may be drawn during the procedure for microRNA analysis.   
8.2.2 Analysis of Metabolon data 
Analytical platform uses gas chromatography-mas s spectrometry method (Metabolon Inc) to provide 
increased overall coverage of small molecules and allows high-throughput data analysis to identify 
biomarkers of disease. Following peak identification and quality control filtering, integrated peak ion counts for each compound in each sample are used for statistical analysis. 
8.2.3 Analysis of MicroRNA data 
MiRNA will be quantified by standard RT-PCR. Expl oratory correlational analysis will be performed 
among the various imaging parameters and biomarkers  using Spearman rank correlation coefficients. 
!
8.3 Health Outcomes Assessment 
The SF-36 health outcomes assessment surveys are for the purpose of exploring the subject’s own 
perceptions about his or her qualit y of life.  The investigator must not influence the subject’s 
assessments.  Every effort should be made to maintain an unbiased assessment. Refer to the flowchart 
for time points. We will be using the SF-36 tool, which is a short-form health survey with 36 questions. 
The endpoint is the 8-scale profile of functional health and well-being scores. 
 
8.4 Laboratory Determinations 
Refer to the Flowchart for specifics and time points. 
 Local laboratories will be used to process blood specimens for complete blood cell counts, 
coagulation tests, chemistry, and urinalysis. 
 The complete blood cell count includes white blood ce ll count (WBC) with differential, platelet count, 
red blood cell count (RBC), hemoglobin (Hgb), and hematocrit (Hct). 
 The chemistry panel includes levels of sodium, potassium, chloride, BUN (or urea), creatinine, 
glucose, calcium, magnesium, phosphorus, AST, ALT,  albumin, total protein, uric acid, CRP, ANA, 
NT-proBNP. 
 Coagulation tests include prothrombin time (PT,  which may be expressed as INR), and partial 
thromboplastin time (PTT). 
 Pregnancy tests (serum or urine) must be done before CMR in women of child bearing potential.   
 
Blood samples may be taken and used for purposes related to this research.  The samples will be stored 
for up to 15 years after the end of the study and then destroyed.  In addition, identifiable samples can be 
destroyed at any time at the request of the subject. 
Targeting RV in PAH  Page 22 
Version1  
 
 
9 Statistical Plan 9.1 Sample Size Determination 
Approximately 10 subjects with PAH and RV dysfuncti on will be randomized in 2:1 ratio to ranolazine or 
placebo. This is a continuation of a study that randomized 14 subjects  in the same fashion. For the 
combined analyses, with 24 subjects, we aim to have  18 evaluable subjects with 12 evaluable subjects 
for ranolazine and 6 for placebo, after accounting for 20 percent dropout/noneval uable. Additionally, there 
are 6 evaluable patients who were observed over 6 months from the prior study.  
 
The imaging analyses will be combined at all sites.  Each site will assess for image quality after the first 
enrolled subject to adjust imaging parameters as necess ary.  Image quality will be assessed for combined 
analysis.   We will be examining different imaging marker s as continuous variables comparing the 
difference pre and post drug treatment. With 12 treated patients and 12 untreated patients (6 in the randomized group and 6 in the observational group), as suming the effect size is 40% with a standard 
deviation of 50%, we will have 87.0%  power to detect the difference bet ween groups with a sample size 
of 12. If the effect size is lower at 35% with a st andard deviation of 50%, we will have 78.2% power to 
detect the difference between groups with a sample size of 12. The unequal randomization is to ensure 
minimum number of subjects are exposed to the treatm ent to provide sufficient information for the study. 
Additionally, we have control patients in the obse rvational group from a prior study who also have 
longitudinal 6 months data.   
 
9.2 Statistical Methods 
9.2.1 General Considerations 
Continuous data  (e.g., age) will be summarized using the fo llowing descriptive su mmary statistics: the 
number of subjects (n), mean, SD, median, minimu m value (min), and maximum value (max). For each 
continuous variable, the corresponding mean, m edian, minimum and maximum will be presented to 1 
decimal place and the SD to 2 decimal places, unless otherwise specified.  
Categorical variables  (e.g., presence of an AE) will be summarized using counts and percentages. 
Percentages will be presented to 1 decimal place. Summaries of cont inuous and ca tegorical data will be 
presented, as appropriate, by treatment, and by schedul ed time points as specified in the study flow 
chart.  
Baseline value  will be defined as the most recent non-missin g measurement collected prior to the initial 
administration of study drug (screening or  Day 1), unless otherwise specified.  
Unscheduled Visits : Subject data obtained during unscheduled visits will not be summarized but 
included in subject data listings only. Unscheduled visit values will not be used to impute missing 
scheduled visit values. 
Incomplete/Missing data : Missing data (e.g., dates, post-base line values) will not be imputed, unless 
otherwise specified; i.e., all missing values and miss ing post-baseline values will remain as missing in all 
statistical analyses and listings, unless otherwise specified. 
Outliers:  No formal statistical analyses will be performed to detect and/or remedy the presence of 
statistical outliers. 
Additionally, all subject data, includi ng derived variables, will be presented in subject data listings; listings 
will display all subjects who were ran domized or enrolled in the study.   
Targeting RV in PAH  Page 23 
Version1  
 
9.2.2 Background Characteristics  
9.2.2.1  Subject Disposition 
The number and percentage of subjects in each disposition category (all randomized population, all 
treated population, completed the treatment, comple ted the study, and discontinued early from treatment 
or study with a breakdown of the reasons for discontinuation) will be summarized based on all 
randomized population. 
9.2.2.2 Demographics and Baseline Characteristics 
Demographics and baseline characteristics (age, sex,  race, ethnicity, weight, height and body mass index 
[BMI]) will be summarized. Summary will be based on the all randomized population.  
9.2.2.3  Prior and Concomitant Medications  
All medications will be coded using the World Health Organization Drug Dictionary Enhanced 
(WHODDE), March 2012 version. Medications used in the study will be summarized in 2 parts:  
 Prior medication:  medication taken before the initial dosin g of study drug in the current study, 
regardless of when the medication administration ended. 
 Concomitant medication:  medication received at or after init ial dosing of study drug, or those 
received before initial dosing with study drug that  continued after initial dosing of study drug.  
If a medication start date is at or after the date of dosing of study drug, then the medication will be 
summarized as concomitant medication regardless of whether the medication end date is missing or not. 
If a medication end date is before the date of dosi ng of study drug, then the medication will be 
summarized as a prior medication regardless of w hether the medication start date is missing or not. Note 
that medication taken before initial dosing of st udy drug and continued after initial dosing will be 
summarized as prior medication, and separately as concomitant medication. 
Concomitant medications will be assigned to each  dosing period based on the start date of the 
medication and the study drug administration dates (concomitant medications taken during the first 
dosing period will be assigned to the first dosing period , and so forth). Note that a concomitant medication 
may be assigned to both dosing periods.  
Concomitant medications will be summarized by do sing period and overall, based on the FAS. Prior 
medications will only be listed. Summary will be based on the all randomized population.  
9.2.2.4  Study Drug Exposure  
Exposure (days) of study drug administration will be estimated as last dose date – first dose date + 1, 
where dose refers to a dose of study drug. 
Exposure to each study drug will be summariz ed based on the all-treated population.  
Study drug exposure will also be presented in an indi vidual subject data listing to indicate the date and 
time of dosing and whether the study drug was taken completely or not.  
9.2.3  Efficacy Analysis 
9.2.3.1 Analysis of Primary Endpoint 
 
Cardiac MRI to assess RV function will be used as primary endpoint for assessment the treatment 
outcome.  All variables from CMR imaging will be summariz ed and listed. Treatment effect will be tested 
using Analysis of covariance (ANOVA), with treatmen t in the model. If the normality assumption fails, non-
parametric method will be employed. Difference betw een drug vs. placebo pre and post treatment will be 
summarized and tested using t-test. Significance will be established at alpha level of 0.05. The efficacy 
analysis will be conducted on the all-treated population. 
Targeting RV in PAH  Page 24 
Version1  
 
9.2.3.2 Analysis of Exploratory Clinical Variables 
The exploratory efficacy endpoint is the estimate and a confidence interval for the difference in 
proportions between the treatment groups. Number and percentage of subjects with high risk profile for 
each treatment group at Week 26 will be provided.  Fisher’s Exact test will be employed to detect the 
difference between Placebo vs Active. Patients with high risk profile are defined as patients with clinical 
worsening events or lack of clinical improvement at the end of the study (week 26).  The primary efficacy 
analysis will be conducted on the all-randomized population.  
 
 Clinical worsening event (per independent clinical  assessment), as defined by at least one of the 
events assessed by the independent clinicia n till end of treatment visit, week 26. 
 Lack of clinical improvement. Clinical improvement  is defined as an increase in 6MWD >or= 15% 
or more from baseline AND an improvement (decrease)  in functional class by at least 1 class by 
end of treatment visit, week 26. 
 
Clinical worsening is evaluated by 2 independent clinicians  at each visit, from date of first dose to end of 
treatment visit. To minimize investigator bias, the data manager will comp are the assessed outcome 
between the 2 independent clinicians. Shall the assessment be different between the 2 independent 
clinicians, the 3rd clinician will be involved to adjudicate the ca se. The evaluation from the adjudicator will 
be used for analysis. At any given time the differenc e exceed more than 30%, the investigator will have a 
conversation with the 2 independent clinicians to narrow the difference.   
For subjects do not experience clinical worsening, the end of the treatment visit (week 26) with 6MWT 
and functional class assessment would determine if there is  no clinical improvement or if there is clinical 
improvement. All efforts should be made to collect the death information in the follow up period. 
 
9.2.3.3 Analysis of Other Exploratory Endpoints 
A. Quality of Life Health Outcome 
The objective is to assess the improvement in qualit y of life of the subjects after being treated with 
ranolazine. Ordinal regression will be employed using SF-36 responses to predict a general health 
perception variable (response optio ns ‘Excellent’, 'Very good', 'Good',  'Fair', and 'Poor'). Items that 
significantly predicted this variabl e were candidates for inclusion in the utility exercise. The efficacy 
analysis will be conducted on the all-randomized population. 
  
      B. Additional exploratory endpoints including additional MRI imaging, metabolic data, microRNA, will be summarized and tested using t-test (paired for pre and post data on the same patient, unpaired for 
Arm 1 and Arm 2 patients). If the normality assumpti on fails, non-parametric method will be employed. 
9.2.3.4 Adverse Events 
AEs will be coded according to MedDRA (Version 15.1) and will be classified as pre-treatment or 
treatment-emergent.   AEs will be graded according to the Common Terminology Criteria for Adverse 
Events (CTCAE) Version 4.0.  
 Pre-treatment adverse events are defined as AEs that developed or worsened after signing the 
informed consent before the start of study drug. 
 Treatment-emergent adverse events  (TEAEs) are defined as AEs with start date or increased 
severity on or after the first study drug dose through the Safety Follow-up Visit.  
9.2.3.5 Clinical Laboratory 
All statistical analyses of laboratory values will be  performed using international system (SI) units. 
Continuous hematology/coagulation and clinical chemistry results will be summarized (raw and change from baseline) at each scheduled time point. The number and percentage of subjects with shift changes 
from baseline based on the laboratory normal ranges will be tabulated at each scheduled time point.  
Targeting RV in PAH  Page 25 
Version1  
 
9.2.3.6 Electrocardiogram 
A summary of raw values and change from baseline values will be provided by dosing period at each 
scheduled time point for the following ECG measurements: heart rate, PR, RR, QRS, QT and QTc 
intervals (QTcB and QTcF). 
9.2.3.7 Vital Signs 
The following vital signs (raw va lues and change from baseline) w ill be summarized by dosing period at 
each scheduled time point: systolic and diastolic blo od pressure (mmHg), body temperature, pulse rate 
(beats per minute [bpm], oxygen saturation).  
9.3 Subject Population(s) for Analysis 
All efficacy analyses will be performed using all-rand omized population.  All safety (AE, lab, vital) 
analyses will be performed using all-treated population. Subject populations are specified within each of 
the analyses section.  
10 Safety and Adverse Events 
10.1 Definitions 
Unanticipated Problems Involvi ng Risk to Subjects or Others 
Any incident, experience, or outcome that meets all of the following criteria:  
 Unexpected in nature, severity, or frequency  (i.e. not described in study-related documents such 
as the IRB-approved protocol or consent form, the investigators brochure, etc) 
 Related or possibly rela ted to participation in the research (i .e. possibly related means there is a 
reasonable possibility that the incident experie nce, or outcome may have been caused by the 
procedures involved in the research) 
 Suggests that the research places subjects or others at greater risk of harm (including physical, 
psychological, economic, or social harm). 
 Adverse Event 
An adverse event  (AE) is any symptom, sign, illness or experience that deve lops or worsens in severity 
during the course of the study.  Intercurrent illnesses or injuries should be regarded as adverse events.  
Abnormal results of diagnostic procedures are cons idered to be adverse events if the abnormality: 
 results in study withdrawal 
 is associated with a serious adverse event 
 is associated with clinical signs or symptoms 
 leads to additional treatment or to further diagnostic tests 
 is considered by the investigator  to be of clinical significance  
 
In the following differentiation between medical history and AEs (see below), the term “condition” may include abnormal physical exam ination findings, symptoms, or diseases. 
 Conditions that started before signing of informed consent and for which no symptoms or 
treatment are present until signing of informed consent are recorded as medical history (e.g. 
seasonal allergy without acute complaints). 
 Conditions that started before signing of info rmed consent and for which symptoms or treatment 
are present after signing of informed consent, at unchanged intensity , are recorded as medical 
history. 
 Conditions that pertain to primary or secondary efficacy variables of this study, i.e. findings in 
CMR and PET and which are considered pre-existing medical conditions, are not considered AEs 
unless there is worsening. This also implies that the indication for the imaging procedure and the 
confirmation of a diagnosis w ill not be considered as an AE. 
 
Serious Adverse Event 
Adverse events are classified as serious or non-serious.  A serious adverse event  is any AE that is:  
Targeting RV in PAH  Page 26 
Version1  
 
 fatal 
 life-threatening 
 requires or prolongs hospital stay 
 results in persistent or sign ificant disability or incapacity 
 a congenital anomaly or birth defect 
 an important medical event 
 Important medical events are those that may not be imm ediately life threatening, but are clearly of major 
clinical significance.   They may jeopardize the s ubject, and may require intervention to prevent one of the 
other serious outcomes noted above.  For example, dr ug overdose or abuse, a seiz ure that did not result 
in in-patient hospitalization, or intensive treatment of bronchospasm in an emergency department would 
typically be considered serious.  
 
All adverse events that do not meet any of the criteria for serious should be regarded as non-serious 
adverse events .  
 
Adverse Event Reporting Period  
The study period during which adverse events must be reported is normally defined as the period from 
the initiation of any study procedures to the end of the study treatm ent follow-up.  For this study, the study 
treatment follow-up is defined as 4 weeks follo wing the last administration of study drug.   
 Preexisting Condition 
A preexisting condition is one that is present at the start of the study.  A preexisting condition should be 
recorded as an adverse event if the frequency, intensity,  or the character of the condition worsens during 
the study period. 
 
General Physical Examination Findings 
At screening, any clinically significant abnormality shoul d be recorded as a preexisting condition.  At the 
end of the study, any new clinically significant find ings/abnormalities that meet the definition of an 
adverse event must also be recorded and documented as an adverse event.   
 
Post-study Adverse Event 
All unresolved adverse events should be followed by the investigator until the events are resolved, the 
subject is lost to follow-up, or the adverse event is otherwise explained.  At the last scheduled visit, the 
investigator should instruct each subject to repo rt any subsequent event(s) that the subject, or the 
subject’s personal physician, believes might reasonabl y be related to participation in this study.  The 
investigator should notify the study sponsor of any death or adverse ev ent occurring at any time after a 
subject has discontinued or terminated study participa tion that may reasonably be related to this study.  
The sponsor should also be notified if the invest igator should become aware of the development of 
cancer or of a congenital anomaly in a subsequently co nceived offspring of a subject that has participated 
in this study.  
 
Abnormal Laboratory Values 
A clinical laboratory abnormality should be document ed as an adverse event if any one of the following 
conditions is met:   
 The laboratory abnormality is not otherwise refu ted by a repeat test to confirm the abnormality 
 The abnormality suggests a disease and/or organ toxicity 
 The abnormality is of a degree that require s active management; e.g. change of dose, 
discontinuation of the drug, more frequent follow-up assessments, further diagnostic investigation, 
etc. 
 Hospitalization, Prolonged Hospitalization or Surgery 
Any adverse event that results in hospitalization or prolonged hospitalization should be documented and 
reported as a serious adverse event unless specifica lly instructed otherwise in this protocol.  Any 
Targeting RV in PAH  Page 27 
Version1  
 
condition responsible for surgery should be documen ted as an adverse event if the condition meets the 
criteria for and adverse event.   
 
Neither the condition, hospitalization, prolonged hosp italization, nor surgery are reported as an adverse 
event in the following circumstances: 
 Hospitalization or prolonged hospitalization for diagnostic or elective surgical procedures for a 
preexisting condition.  Surgery should not be reported as an outcome of an adverse event if the 
purpose of the surgery was elective or diagnostic and the outcome was uneventful. 
 Hospitalization or prolonged hospitalization requir ed to allow efficacy measurement for the study. 
 Hospitalization or prolonged hospitalization for ther apy of the target disease of the study, unless it 
is a worsening or increase in frequency of hos pital admissions as judged by the clinical 
investigator. 
10.2 Recording of Adverse Events 
At each contact with the subject, the investigator mu st seek information on adverse events by specific 
questioning and, as appropriate, by examination.  Information on all adverse events should be recorded 
immediately in the source document, and also in the appropriate adverse event m odule of the case report 
form (CRF).  All clearly related signs, symptoms , and abnormal diagnostic procedures results should 
recorded in the source document, though should be grouped under one diagnosis. 
 
All adverse events occurring during the study period must be recorded.  T he clinical course of each event 
should be followed until resolution, stabilization, or unt il it has been determined t hat the study treatment or 
participation is not the cause.  Serious adverse events  that are still ongoing at the end of the study period 
must be followed up to determine the final outcome.  Any serious adverse event that occurs after the 
study period and is considered to be possibly related to  the study treatment or study participation should 
be recorded and reported immediately. 
10.3 Reporting of Serious Adverse Events and Unanticipated Problems 
Site investigators must conform to the adverse event  reporting timelines, formats and requirements of the 
various entities to which they are responsible, but at  a minimum those events that must be reported are 
those that are: 
 related to study participation, 
 unexpected, and  
 serious or involve risks to subjects or others  
(see definitions, section 8.1).    
If the report is supplied as a narrative, the minimum nec essary information to be provided at the time of 
the initial report includes: 
 Study identifier 
 Subject number 
 A description of the event 
 Date of onset  Current status 
 Whether study was discontinued 
 The reason why the event is classified as serious 
 Investigator assessme nt of the association 
between the event and study drug  
 
Any study-related unanticipated problem posing risk of harm to subjects or  others, and any type of 
serious adverse event, must be reported to Penn princi ple investigator. To report such events, a Serious 
Adverse Event (SAE) form must be completed by t he investigator and faxed or emailed to the study 
sponsor within 24 hours.  The investigator will keep a c opy of this SAE form on file at the study site.   
 
Within the following 48 hours, the investigator mu st provide further information on the serious adverse 
event or the unanticipated problem in the form of a wr itten narrative.  This should include a copy of the 
completed Serious Adverse Event form, and any other diagnostic information that will assist the 
understanding of the event.  Significant new inform ation on ongoing serious adverse events should be 
provided promptly to the Penn principle investigator.  
Targeting RV in PAH  Page 28 
Version1  
 
 
Reporting Procedures for Potential Endpoints and Endpoints 
Events that are potential endpoints: hospitalization for PAH, death, worsening of PAH, lung or heart-lung 
transplant, atrial septostomy or other interventional procedure specifically for RH failure or PAH, decline 
of 6-MWD, increase in Borg Dyspnea Index and Incr ease in WHO-functional class initially will not be 
considered as serious adverse events but will be handl ed as efficacy endpoints.  They will not be subject 
to the immediate submission require ments for SAEs in this study and w ill not require the investigator’s 
causality assessment.  The site inve stigator will make the initial determ ination to classify these events as 
endpoints or SAEs.  Events that  are equivocal will be adjudicated by t he medical monitor in real time.  For 
these potential endpoints, an SAE eCRF will only be comp leted if the DSMB deter mines that a specific 
event does not meet the criteria for the relevant  endpoint (ie, the potential endpoint is negatively 
adjudicated).  Once an investigator is notified of th e negative adjudication, the investigator must complete 
and submit a SAE eCRF within 24 hours.  The DSMB will be requested to follow the occurrence of these 
events to see if specific action needs to be taken during the course of the study.   
 In addition, the DSMB will review all fatal endpoints to evaluate whether the caus e of death is due to a 
serious adverse event that is a specific concer n for the study drug or which may be individually 
informative, such as an anaphylactic reaction, rha bdomyolysis, or Stevens-Johnson syndrome.  If such an 
event is detected, the DSMB will notify the inve stigator to submit the SAE per local reporting 
requirements.   
10.3.1 Investigator reporting: notifying the Penn IRB 
This section describes the requirements for safety reporting by investigators who are Penn faculty, 
affiliated with a Penn research site, or otherwise responsible for safety repo rting to the Penn IRB. The 
University of Pennsylvania IRB (P enn IRB) requires expedited reporting of those events related to study 
participation that are unforeseen and indicate that part icipants or others are at increased risk of harm.  
The Penn IRB will not acknowledge safety reports or  bulk adverse event submissions that do not meet 
the criteria outlined below.  The Penn IRB requires researchers to submit reports of the following 
problems within 10 working days from the time the investigator becomes aware of the event: 
 Any adverse event (regardless of whether the event is serious or non-serious, on-site or off-site) 
that occurs any time during or after the resear ch study, which in the opinion of the principal 
investigator is: 
Unexpected (An event is “unexpect ed” when its specificity and severity are not accurately reflected 
in the protocol-related documents, such as the IRB-approved research protocol, any applicable 
investigator brochure, and the current IRB-approved informed consent document and other 
relevant sources of information, such as product labeling and package inserts.) 
AND 
Related to the research procedures (An event is “related to the research procedures” if in the 
opinion of the principal investigator or sponsor, t he event was more likely than not to be caused by 
the research procedures.) 
 Reporting Process 
Unanticipated problems posing risks to subjects or others as noted above will be reported to the Penn 
IRB using the form: “Unanticipated Problems Posing Risks to Subjects or Others Including Reportable 
Adverse Events” or as a written repo rt of the event (including a descri ption of the event with information 
regarding its fulfillment of the above criteria, follow- up/resolution and need for revision to consent form 
and/or other study documentation). 
 Copies of each report and documentation of IRB notif ication and receipt will be kept in the Clinical 
Investigator’s study file. 
 
Other Reportable events: 
For clinical drug trials, the following even ts are also reportable to the Penn IRB: 
Targeting RV in PAH  Page 29 
Version1  
 
 Any adverse experience that, even without det ailed analysis, represents a serious unexpected 
adverse event that is rare in  the absence of drug exposure (such as agranulocytosis, hepatic 
necrosis, Stevens-Johnson syndrome). 
 Any adverse event that would cause the sponsor to  modify the investigator s brochure, protocol or 
informed consent form, or would prompt other acti on by the IRB to assure protection of human 
subjects. 
 Information that indicates a change to the risks or  potential benefits of t he research, in terms of 
severity or frequency. For example:  
– An interim analysis indicates that participants have a lower rate of response to treatment than 
initially expected. 
– Safety monitoring indicates that a particular si de effect is more severe, or more frequent than 
initially expected. 
– A paper is published from another study that show s that an arm of your research study is of no 
therapeutic value. 
 Change in FDA safety labeling or withdrawal from  marketing of a drug, device, or biologic used in 
a research protocol. 
 Breach of confidentiality 
 Change to the protocol taken without prior IRB re view to eliminate apparent immediate hazard to a 
research participant. 
 Incarceration of a participant when the res earch was not previously  approved under Subpart C 
and the investigator believes it is in the best in terest of the subject to remain on the study. 
 Complaint of a participant when the complaint indicates unexpected risks or the complaint cannot 
be resolved by the research team. 
 Protocol violation (meaning an accidental or unintentional deviation from the IRB approved 
protocol) that in the opinion of t he investigator placed one or more participants at increased risk, or 
affects the rights or welfare of subjects. 
10.3.2 Investigator reporting: Notifying a non-Penn IRB 
Investigators who are not Penn faculty or affiliated with  a Penn research site are responsible for safety 
reporting to their local IRB.  Investigators are resp onsible for complying with their local IRB’s reporting 
requirements, though must submit the required reports to their IRB no later than 10 working days.  Copies 
of each report and documentation of IRB notification and  receipt will be kept in the investigator’s study 
file. 
 
10.4 Medical Monitoring 
It is the responsibility of the Principal Investigator to ov ersee the safety of the study  at his/her site.  This 
safety monitoring will include care ful assessment and appropr iate reporting of adv erse events as noted 
above.  Medical monitoring will include a regular a ssessment of the number and type of serious adverse 
events.  Safety will be closely monitored by the site investigators on an ongoing bas is for subjects on both 
treatment and placebo arms. A Data and Safety Monito ring Committee (DSMB) is planned to monitor the 
safety of this study.   
10.5 Data and Safety Monitoring Board 
An independent DSMB will be established to assure the safety of participants in this trial.  The DSMB will 
review the study for safety and overall study conduct.  At the end of the study they may adjudicate final 
outcome based on the clinical  information.  The membership of t he DSMB as well as the responsibilities 
and procedures used to carry out thes e responsibilities are described separ ately in the DSMB charter.   
 
Targeting RV in PAH  Page 30 
Version1  
 
11 Data Handling and Record Keeping 
11.1 Confidentiality 
Information about study subjects will be kept confidential and managed according to the requirements of 
the Health Insurance Portability and Accountability Ac t of 1996 (HIPAA).  Thos e regulations require a 
signed subject authorization informin g the subject of the following:  
 What protected health information (PHI) will be collected from subjects in this study 
 Who will have access to that information and why 
 Who will use or disclose that information 
 The rights of a research subject to revoke their authorization for use of their PHI.  
 
In the event that a subject revokes authorization to collect or use PHI, the investigator, by regulation, 
retains the ability to use all information collected prio r to the revocation of subject authorization.  For 
subjects that have revoked authorization to collect  or use PHI, attempts should be made to obtain 
permission to collect at least vital status (i.e. that t he subject is alive) at the end of their scheduled study 
period. 
11.2 Source Documents 
Source data is all information, original records of cl inical findings, observations, or other activities in a 
clinical trial necessary for the reconstruction and eval uation of the trial.  Source data are contained in 
source documents.  Examples of these original docu ments, and data records include: hospital records, 
clinical and office charts, laboratory notes, memora nda, subjects’ diaries or evaluation checklists, 
pharmacy dispensing records, recorded data from aut omated instruments, copies or transcriptions 
certified after verification as being accurate and comp lete, microfiches, photogr aphic negatives, microfilm 
or magnetic media, x-rays, subject files, and record s kept at the pharmacy, at the laboratories, and at 
medico-technical departments involved in the clinical trial. 
11.3 Data Management Plan 
We will create a shared database with common data  definitions.  This dat abase will be programmed in 
REDCap (Research Electronic Data Capture).  REDC ap is a secure, web-based application with the 
capacity for direct export to Ex cel and common statistical packages (SPSS, SAS, Strata, R).  REDCap 
has electronic CRFs, real-time data entry validation,  audit trails, user authentication, data logging and 
encryption.  It is HIPAA compliant with mechani sms in place to ensure confidentiality. 
 
Specific forms will be used for each component of the subject’s progress.  The forms and data dictionary 
will be available online for all individuals who perf orm data entry.  Research personnel, trained on data 
definitions, will enter data via web-based data forms afte r abstraction from the primary medical record and 
source documents.  The multisit e feature of REDCap will be used to restrict data viewing by 
investigators.   In addition, logical data checks will be used to assess data quality for miss-entry.  Suspect 
data entries will be flagged for re-review and confirmati on by the investigative team at each site.  When 
data are complete and all suspect entries addressed fo r a time period, the database will be “locked” for 
analysis.  Analysis will use onl y this final locked version. 
11.4 Data Sharing Plan 
Clinical data will be exported from REDCap into proper statistical software format for analysis.   The final 
dataset will be provided in proper fo rmat to investigators participating in  data analysis from each site.  The 
mode of data sharing will be by downloading from RE DCap from secure accounts.  Data will be secured 
by electronic safeguards.  Image data will be shared between institutions through a secure file share.  Prior to sharing, all data and all images will be anonymized to strip all identifiers to protect the 
human participants.   
11.5 Records Retention 
It is the investigator’s responsibility to retain study essential documents for at least 2 years after the last 
approval of a marketing application in their count ry and until there are no pending or contemplated 
Targeting RV in PAH  Page 31 
Version1  
 
marketing applications in their country or at least 2 years have elapsed since the formal discontinuation of 
clinical development of the investigational produc t.  These documents should be retained for a longer 
period if required by an agreement with the s ponsor.  In such an instance, it  is the responsibility of the 
sponsor to inform the investigator/institution as to when these documents no longer need to be retained. 
11.6 Management of Information for Multi-Center Research 
University of Pennsylvania will be the coordinating ce nter as well as a site for recruitment and data 
collection for the trial.  Brigham and Women’s Hospit al and the University of Maryland will be the other 
sites.  Dr. Han (Penn) and Dr. Waxman (BWH), the PIs of the grant together with the Project Manager at 
Penn will supervise all aspects of the project, includi ng management of project timelines, management of 
data collected from each site, safety reporting, and submitting progress reports.  There will be regular, 
documented communication (e.g. teleconferences) with the participating sites to update and inform all 
participating sites about progress of t he study.   As the lead investigator at the coordinating institution, Dr. 
Han will receive data and reports from other sites in a timely manner and distribute them to the Penn IRB 
and other sites as required.  The PI for each site will be the regulatory sponsor for their site and will be 
responsible for enrollment, managing IRB communications  and data quality.  The DSMB will also monitor 
participant safety and evaluate t he progress of the study.   
 
12 Study Monitoring, Auditing, and Inspecting 
12.1 Study Monitoring Plan 
The Principal Investigator at each site  is responsible for assigning staff for monitoring.  Enrollment will be 
complete when all subjects are enrolle d into the trial across sites.   The following will occur after the first 
subject is enrolled at each site, and throughout the trial:    
 
1) Informed consent documentation w ill be reviewed for all subjects 
2) Eligibility criteria 
3) Safety Monitoring (adverse event documentation and assessment) 
4) Regulatory documentation (IRB – amendm ents, continuing review  and reportable events) 
 
12.2 Regulatory Documents Reviewed 
The Regulatory Documents will be maintained in the Regulatory Binder.  The Regulatory Binder may be 
reviewed by the monitor during any visit.  The monito r will review the regulatory binder for completeness 
and will assure that the CRFs are being completed.      
12.3  Auditing and Inspecting 
The investigator will permit study-related monitori ng, audits, and inspections by the EC/IRB, government 
regulatory bodies, and University compliance and quality assurance groups of all study related 
documents (e.g. source documents, regulatory document s, data collection instrume nts, study data etc.).  
The investigator will ensure the capability for insp ections of applicable study-related facilities (e.g. 
pharmacy, diagnostic laboratory, etc.).  
Participation as an investigator in this study imp lies acceptance of potential inspection by government 
regulatory authorities and applicable University compliance and quality assurance offices.  
13 Ethical Considerations 
This study is to be conducted accordance with appl icable US government regulations and international 
standards of Good Clinical Practice, and applicabl e institutional research policies and procedures. 
 
This protocol and any amendments will be submitt ed to a properly constituted independent Ethics 
Committee (EC) or Institutional Review  Board (IRB), in agreement with local legal prescriptions, for formal 
Targeting RV in PAH  Page 32 
Version1  
 
approval of the study conduct.  The decision of the EC/IRB concerning the conduct of the study will be 
made in writing to the investigator  and a copy of this decision w ill be provided to the sponsor before 
commencement of this study.  The investigator shoul d provide a list of EC/IRB members and their affiliate 
to the sponsor.  
All subjects for this study will be provided a consen t form describing this study and providing sufficient 
information for subjects to make an informed decision about their participation in this study.  This consent 
form will be submitted with the protocol for review and approval by the EC/IRB for the study.  The formal 
consent of a subject, using the EC/IRB-approved c onsent form, must be obtained before that subject 
undergoes any study procedure.  The consent form must be signed by t he subject or legally acceptable 
surrogate, and the investigator-designated re search professional obtaining the consent.  
14 Study Finances 
14.1 Funding Source 
 
Gilead Science Inc  
14.2 Conflict of Interest 
Any investigator who has a conflict of interest with th is study (patent ownership, royalties, or financial gain 
greater than the minimum allowable by  their institution, et c.) must have the conflic t reviewed by a properly 
constituted Conflict of Interest Committee with  a Committee-sanctioned conflict management plan that 
has been reviewed and approved by the study sponsor prio r to participation in this study.  All University of 
Pennsylvania investigators will follow the applicabl e University conflict of interest policies. 
 
15 Publication Plan 
A Publication Committee will include Dr. Han and Dr. Waxman, and will be open to co-investigators and 
collaborators.  The purpose of the Publication Co mmittee is to effectively manage and oversee the 
primary, secondary and ancillary publications gener ated from the study while complying with all 
applicable guidelines and policies.  This includes delivering high-quality publications that address the 
primary evidence needs identified and prioritized by any collaborators, co-investigators, and the 
Publication Committee. 
16 References 
 
1. Bogaard HJ, Abe K, Vonk Noorde graaf A, Voelkel NF. The right ve ntricle under pressure: Cellular 
and molecular mechanisms of right-heart failure in pulmonary hypertension. Chest . 2009;135:794-804 
2. Ryan J, Bloch K, Archer SL. Rodent models of  pulmonary hypertension: Harmonisation with the 
world health organisation's categorisation of human ph. Int J Clin Pract Suppl . 2011:15-34 
3. Tuder RM, Davis LA, Graham BB. Targeting energetic metabolism: A new frontier in the 
pathogenesis and treatment of pulmonary hypertension. Am J Respir Crit Care Med . 2011;185:260-266 
4. Lee JK, Kodama I, Honjo H, Anno T, Kamiya K, Toyama J. Stage-dependent changes in membrane currents in rats with monocrot aline-induced right ventricular hypertrophy. Am J Physiol . 
1997;272:H2833-2842 
5. Sharma S, Taegtmeyer H, Adrogue J, Raze ghi P, Sen S, Ngumbela K, Essop MF. Dynamic 
changes of gene expression in hypoxia-induced right v entricular hypertrophy. Am J Physiol Heart Circ 
Physiol . 2004;286:H1185-1192 
6. Kleiman RB, Houser SR. Outward currents in  normal and hypertrophied feline ventricular 
myocytes. Am J Physiol . 1989;256:H1450-1461 
7. Bonnet S, Michelakis ED, Porter CJ, Andra de-Navarro MA, Thebaud B, Haromy A, Harry G, 
Moudgil R, McMurtry MS, Weir EK, Archer SL. An abnormal mitochondrial-hypoxia inducible factor-
1alpha-kv channel pathway disrupts oxygen sensing and tr iggers pulmonary arterial hypertension in fawn 
hooded rats: Similarities to human pulmonary arterial hypertension. Circulation . 2006;113:2630-2641 
Targeting RV in PAH  Page 33 
Version1  
 
8. Michelakis E, McMurtry M, Wu X, Dyck J,  Moudgil R, Hopkins T, Lopaschuk G, Puttagunta L, 
Waite R, Archer S. Dichloroacetate, a metabolic  modulator, prevents and reverses chronic hypoxic 
pulmonary hypertension in rats: Role of increased expression and activity of voltage-gated potassium 
channels. Circulation . 2002;105:244-250 
9. Piao L, Fang YH, Cadete VJ, Wietholt C, Urboni ene D, Toth PT, Marsboom G, Zhang HJ, Haber 
I, Rehman J, Lopaschuk GD, Archer SL. The inhibi tion of pyruvate dehydrogenase kinase improves 
impaired cardiac function and electrical remodelin g in two models of right ventricular hypertrophy: 
Resuscitating the hibernating right ventricle. J Mol Med (Berl) . 2010;88:47-60 
10. Oikawa M, Kagaya Y, Otani H, Sakuma M, Demach i J, Suzuki J, Takahashi T, Nawata J, Ido T, 
Watanabe J, Shirato K. Increased [18f]fluorodeoxyglucose accumulation in  right ventricular free wall in 
patients with pulmonary hypertensio n and the effect of epoprostenol. J Am Coll Cardiol . 2005;45:1849-
1855 
11. Basu S, Alzeair S, Li G, Dadparvar S, Alavi A.  Etiopathologies associated with intercostal muscle 
hypermetabolism and prominent right ventricle visualization on 2-deoxy-2[f-18]fluoro-d-glucose-positron 
emission tomography: Significance of an incidental  finding and in the setting of a known pulmonary 
disease. Mol Imaging Biol . 2007;9:333-339 
12. Chaitman BR, Skettino SL, Parker JO, Hanley P,  Meluzin J, Kuch J, Pepine CJ, Wang W, Nelson 
JJ, Hebert DA, Wolff AA. Anti-ischemic effects and long-term survival during ranolazine monotherapy in 
patients with chronic severe angina. J Am Coll Cardiol . 2004;43:1375-1382 
13. Chaitman BR, Pepine CJ, Parker JO, Skopal J, Chumakova G, Kuch J, Wang W, Skettino SL, 
Wolff AA. Effects of ranolazine with atenolol, amlodipi ne, or diltiazem on exercise tolerance and angina 
frequency in patients with severe chronic angina: A randomized controlled trial. JAMA . 2004;291:309-316 
14. Clarke B, Spedding M, Patmore L, McCormack JG. Protective effects of ranolazine in guinea-pig 
hearts during low-flow ischaemia and their associatio n with increases in active pyruvate dehydrogenase. 
Br J Pharmacol . 1993;109:748-750 
15. Clarke B, Wyatt KM, McCormack JG. Ranolazi ne increases active pyruvate dehydrogenase in 
perfused normoxic rat hearts: Evidence for an indirect mechanism. J Mol Cell Cardiol . 1996;28:341-350 
16. Fang YH, Piao L, Hong Z, Toth PT, Marsboom G, Bache-Wiig P, Rehman J, Archer SL. 
Therapeutic inhibition of fatty acid oxidation in ri ght ventricular hypertrophy: Exploiting randle's cycle. J 
Mol Med (Berl) . 2012;90:31-43 
17. Hasenfuss G, Maier LS. Mechanism of acti on of the new anti-ischemia drug ranolazine. Clin Res 
Cardiol . 2008;97:222-226 
18. van de Veerdonk MC, Kind T, Marcus JT, Ma uritz GJ, Heymans MW, Bogaard HJ, Boonstra A, 
Marques KM, Westerhof N, Vonk-Noordegraaf A. Progressi ve right ventricular dysfunction in patients with 
pulmonary arterial hypertension responding to therapy. J Am Coll Cardiol . 2011;58:2511-2519 
19. Deng Z, Morse J, Slager S, Cuervo N, Moore K,  Venetos G, Kalachikov S,  Cayanis E, Fischer S, 
Barst R, Hodge S, Knowles J. Familial primary pulmonary hypertension (gene pph1) is caused by 
mutations in the bone morphogenetic protein receptor-ii gene. American Journal of Human Genetics . 
2000;67:737-744 
20. Lane K, Machado R, Pauciulo M, Thomson J, Phillips Jr, Loyd J, Nichols W, Trembath R. 
Heterozygous germline mutations in bmpr2, encoding a tgf-beta receptor, cause familial primary 
pulmonary hypertension. The international pph consortium. Nature Genetics . 2000;26:81-84 
21. Thomson J, Machado R, Pauciulo M, Morgan N, Humbert M, Elliott G, Ward K, Yacoub M, 
Mikhail G, Rogers P, Newman J, Wh eeler L, Higenbottam T, Gibbs J, Egan J, Crozier A, Peacock A, 
Allcock R, Corris P, Loyd J, Trem bath R, Nichols W. Sporadic primary pulmonary hypertension is 
associated with germline mutations of the gene enc oding bmpr-ii, a receptor member of the tgf-beta 
family. Journal of Medical Genetics . 2000;37: 741-745 
22. Machado R, Pauciulo M, Thomson J, Lane K, Morgan N, Wheeler L, Phillips J, Newman J, 
Williams D, Galiè N, Manes A, McNeil K, Yacoub M, Mikhail G, Rogers P, Corris  P, Humbert M, Donnai 
D, Martensson G, Tranebjaerg L, Loyd J, Tremba th R, Nichols W. Bmpr2 haploinsufficiency as the 
inherited molecular mechanism for primary pulmonary hypertension. American Journal of Human 
Genetics . 2001;68:92-102 
23. Newman J, Wheeler L, Lane K, Loyd E, Gaddipat i R, Phillips Jr, Loyd J. Mutation in the gene for 
bone morphogenetic protein receptor ii as a cause of primary pulmonary hypertension in a large kindred. 
New England Journal of Medicine . 2001;345:319-324. [Erratum, N Engl J Med 2001;2345:1506, 
2002;2346:1258.] 
Targeting RV in PAH  Page 34 
Version1  
 
24. Trembath R, Thomson J, Machado R, Morgan N,  Atkinson C, Winship I, Simonneau G, Galie N, 
Loyd J, Humbert M, Nichols W, Morrell N, Berg J,  Manes A, McGaughran J, Pauciulo M, Wheeler L. 
Clinical and molecular genetic features of pulmonary  hypertension in patients with hereditary hemorrhagic 
telangiectasia. New England Journal of Medicine . 2001;345:325-334 
25. Small EM, Olson EN. Pervasive roles of  micrornas in cardiovascular biology. Nature . 
2011;469:336-342 
26. Drake JI, Bogaard HJ, Mizuno S, Clifton B, Xi e B, Gao Y, Dumur CI, Fawcett P, Voelkel NF, 
Natarajan R. Molecular signature of a right heart failure program in chronic severe pulmonary 
hypertension. Am J Respir Cell Mol Biol . 2011;45:1239-1247 
27. Creemers EE, Tijsen AJ, Pinto YM. Circulating micrornas: Novel biomarkers and extracellular 
communicators in cardiovascular disease? Circ Res . 2012;110:483-495 
28. Park IH, Zhao R, West JA, Yabuuchi A, H uo H, Ince TA, Lerou PH, Lensch MW, Daley GQ. 
Reprogramming of human somatic cells to pluripotency with defined factors. Nature . 2008;451:141-146 
29. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. Induction of 
pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131:861-872 
30. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewic z-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir 
GA, Ruotti V, Stewart R, Slukvin, II, Thomson JA. In duced pluripotent stem cell lines derived from human 
somatic cells. Science . 2007;318:1917-1920 
31. Ren Y, Lee MY, Schliffke S, Paavola J, Amos PJ, Ge X, Ye M, Zhu S, Senyei G, Lum L, Ehrlich 
BE, Qyang Y. Small molecule wnt inhibitors enhan ce the efficiency of bmp-4-directed cardiac 
differentiation of human pluripotent stem cells. J Mol Cell Cardiol . 2011;51:280-287 
32. Zhang J, Wilson GF, Soerens AG, Koonce CH, Yu J, Palecek SP, Thomson JA, Kamp TJ. 
Functional cardiomyocytes derived from  human induced pluripotent stem cells. Circ Res . 2009;104:e30-
41 33. Itzhaki I, Maizels L, Huber I, Zwi-Dantsis L, Ca spi O, Winterstern A, Feldman O, Gepstein A, 
Arbel G, Hammerman H, Boulos M, Gepstein L. Mode lling the long qt syndrome with induced pluripotent 
stem cells. Nature . 2011;471:225-229 
34. Moretti A, Bellin M, Welling A, Jung CB, Lam JT, Bott-Flugel L, Dorn T, Goedel A, Hohnke C, 
Hofmann F, Seyfarth M, Sinnecker D, Schomig A, Laugwitz KL. Patient-specific induced pluripotent stem-
cell models for long-qt syndrome. N Engl J Med . 2010;363:1397-1409 
35. Carvajal-Vergara X, Sevilla A, D'Souza SL, Ang YS, Schaniel C, Lee DF, Yang L, Kaplan AD, 
Adler ED, Rozov R, Ge Y, Cohen N, Edelmann LJ, C hang B, Waghray A, Su J, Pardo S, Lichtenbelt KD, 
Tartaglia M, Gelb BD, Lemischka IR. Patient-specifi c induced pluripotent stem-cell-derived models of 
leopard syndrome. Nature . 2010;465:808-812 
36. Stone PH, Gratsiansky NA, Blokhin A, Huang IZ, Meng L. Antianginal efficacy of ranolazine when 
added to treatment with amlodipine: The erica (efficacy of ranolazine in chronic angina) trial. J Am Coll 
Cardiol . 2006;48:566-575 
37. Sendon JL, Lee S, Cheng ML, Ben-Yehuda O. Effe cts of ranolazine on exercise tolerance and 
angina frequency in patients with severe chroni c angina receiving maximally-tolerated background 
therapy: Analysis from the combinat ion assessment of ranolazine in stable angina (carisa) randomized 
trial. Eur J Prev Cardiol . 2012;19:952-959 
38. Rautaharju PM, Zhang ZM, Prineas R, Heiss G. Assessment of prolonged qt and jt intervals in 
ventricular conduction defects. Am J Cardiol . 2004;93:1017-1021 
 
 